✦ LIBER ✦

P.4.044 Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study

✍ Scribed by B. Winblad; A. Wimo; A.-L. Wetterholm; A. Haglund; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; R. Zhang; L. Burger; R. Schindler

Book ID: 119577272
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 144 KB
Volume: 13
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(03)92238-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.4.041 Donepezil is a well-tolerated lo

P.4.041 Donepezil is a well-tolerated long-term treatment for patients with mild to moderate Alzheimer's disease: Results from a patient cohort who completed a one-year placebo-controlled study and participated in a two-year follow-up study

✍ B. Winblad; K. Engedal; H. Soininen; F.R.J. Verhey; G. Waldemar; A. Wimo; A.-L. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 286 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

P4-337: Dimebon improves cognition, func

P4-337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study

✍ Doody, Rachelle S.; Gavrilova, Svetlana; Thomas, Ronald; Aisen, Paul; Bachurin, 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB

P4-334: Eighteen-month data from an open

P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease

✍ Cummings, Jeffrey; Doody, Rachelle; Gavrilova, Svetlana; Sano, Mary; Aisen, Paul 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 66 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

P.4.006 Long-term efficacy and safety be

P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease

✍ H.-J. Moebius; B. Reisberg; F. Schmitt; R. Doody 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 274 KB